Diagnostic potential of serum proteomic patterns in prostate cancer.

PURPOSE The serum prostate specific antigen test has been widely used in the last decade as an effective screening tool for prostate cancer (CaP). However, the high false-positive rate of the serum prostate specific antigen test necessitates the development of more accurate diagnostic and prognostic biomarkers for CaP. Promising diagnostic potential of serum protein patterns detected by surface enhanced laser desorption/ionization time of flight mass spectrometry for CaP has recently been reported. Independent evaluation of this new technology is warranted to realize its translational utility. We determined whether serum protein profiling by surface enhanced laser desorption/ionization time of flight mass spectrometry and a decision tree algorithm classification system could accurately discriminate between patients with CaP and unaffected individuals. MATERIALS AND METHODS Proteomic spectra of crude serum were generated using the Ciphergen ProteinChip System and pattern detection was performed using Biomarker Patterns Software (Ciphergen Biosystems, Inc., Fremont, California). A total of 106 patients with CaP and 56 controls were randomly allocated to a training set and a test set. The training set, which consisted of 44 patients with cancer and 30 controls, was used to build a decision tree algorithm. The test set, which consisted of 62 patients with cancer and 26 controls, was used in blinded fashion to validate the decision tree. RESULTS Accuracy of classification using the test set was 67% and 42% for the weak cation exchange array and the copper metal affinity capture array, respectively. Combined spectral data from the weak cation exchange and copper metal affinity capture arrays generated an algorithm that achieved 85% sensitivity and 85% specificity for the detection of CaP. CONCLUSIONS These preliminary findings support recent observations that complex protein profiles have promising potential for the early detection of CaP and warrant future studies with streamlined technology. Furthermore, the combined effect of using 2 array types can greatly enhance the ability of protein profile patterns, suggesting the potential usefulness of alternative approaches to evaluate this new emerging technology.

[1]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[2]  O John Semmes,et al.  Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  Dr. Ron Short Diagnosis? , 1987, The Lancet.

[4]  G. Wright,et al.  Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. , 2001, The American journal of pathology.

[5]  Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). , 2000, Oncology.

[6]  E. Petricoin,et al.  Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.

[7]  M. Barry Prostate-Specific–Antigen Testing for Early Diagnosis of Prostate Cancer , 2001 .

[8]  S. Ethier,et al.  Differential screening and mass mapping of proteins from premalignant and cancer cell lines using nonporous reversed-phase HPLC coupled with mass spectrometric analysis. , 2001, Analytical chemistry.

[9]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.

[10]  D. Chan,et al.  Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.

[11]  S R Gullans,et al.  DNA microarray analysis of complex biologic processes. , 2001, Journal of the American Society of Nephrology : JASN.

[12]  Uwe Claussen,et al.  Mass spectrometry meets chip technology: A new proteomic tool in cancer research? , 2001, Electrophoresis.

[13]  M. Barry,et al.  Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. , 2001, The New England journal of medicine.

[14]  Paulo J. G. Lisboa,et al.  A review of evidence of health benefit from artificial neural networks in medical intervention , 2002, Neural Networks.

[15]  T. Golub,et al.  DNA microarrays in clinical oncology. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  T. Keough,et al.  Tandem mass spectrometry methods for definitive protein identification in proteomics research , 2000, Electrophoresis.

[17]  B. Weber,et al.  Cancer genomics. , 2002, Cancer cell.

[18]  M. Lise,et al.  Protein profiles in sera of patients with malignant cutaneous melanoma. , 2000, Rapid communications in mass spectrometry : RCM.

[19]  Sarunas Raudys How good are support vector machines? , 2000, Neural Networks.

[20]  Ahmedin Jemal,et al.  Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.